MA35064B1 - Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie - Google Patents

Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie

Info

Publication number
MA35064B1
MA35064B1 MA36364A MA36364A MA35064B1 MA 35064 B1 MA35064 B1 MA 35064B1 MA 36364 A MA36364 A MA 36364A MA 36364 A MA36364 A MA 36364A MA 35064 B1 MA35064 B1 MA 35064B1
Authority
MA
Morocco
Prior art keywords
thieno
pyrimidine derivatives
treating arrhythmia
arrhythmia
relates
Prior art date
Application number
MA36364A
Other languages
English (en)
Inventor
Derek Edward John
John Ford
Original Assignee
Xention Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44071904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35064(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Xention Ltd filed Critical Xention Ltd
Publication of MA35064B1 publication Critical patent/MA35064B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des composés thiénopyrimidine qui sont des inhibiteurs de canaux potassiques. Elle concerne également des compositions pharmaceutiques comprenant les composés et leur utilisation dans le traitement de l'arythmie.
MA36364A 2011-04-01 2012-03-29 Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie MA35064B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1105659.5A GB201105659D0 (en) 2011-04-01 2011-04-01 Compounds
PCT/GB2012/050710 WO2012131379A1 (fr) 2011-04-01 2012-03-29 Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie

Publications (1)

Publication Number Publication Date
MA35064B1 true MA35064B1 (fr) 2014-04-03

Family

ID=44071904

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36364A MA35064B1 (fr) 2011-04-01 2012-03-29 Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie

Country Status (42)

Country Link
US (1) US9249155B2 (fr)
EP (1) EP2694518B1 (fr)
JP (1) JP5826374B2 (fr)
KR (1) KR20140023332A (fr)
CN (1) CN103492392B (fr)
AP (1) AP2013007198A0 (fr)
AR (1) AR088735A1 (fr)
AU (1) AU2012235882B2 (fr)
BR (1) BR112013025236A2 (fr)
CA (1) CA2831493A1 (fr)
CL (1) CL2013002789A1 (fr)
CO (1) CO6801756A2 (fr)
CR (1) CR20130488A (fr)
CU (1) CU24173B1 (fr)
CY (1) CY1117025T1 (fr)
DK (1) DK2694518T3 (fr)
EA (1) EA201301111A1 (fr)
EC (1) ECSP13012988A (fr)
ES (1) ES2558563T3 (fr)
GB (1) GB201105659D0 (fr)
GT (1) GT201300225A (fr)
HK (2) HK1193096A1 (fr)
HR (1) HRP20151340T1 (fr)
HU (1) HUE028438T2 (fr)
IL (1) IL228555A0 (fr)
MA (1) MA35064B1 (fr)
ME (1) ME02314B (fr)
MX (1) MX335937B (fr)
NI (1) NI201300100A (fr)
PE (1) PE20141021A1 (fr)
PL (1) PL2694518T3 (fr)
PT (1) PT2694518E (fr)
RS (1) RS54458B1 (fr)
RU (1) RU2013148627A (fr)
SG (1) SG193578A1 (fr)
SI (1) SI2694518T1 (fr)
SM (1) SMT201500322B (fr)
TN (1) TN2013000377A1 (fr)
TW (1) TWI516265B (fr)
UA (1) UA110131C2 (fr)
WO (1) WO2012131379A1 (fr)
ZA (1) ZA201307085B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014078957A1 (fr) * 2012-11-20 2014-05-30 The Royal Institution For The Advancement Of Learning/Mcgill University Inhibiteurs thiénopyrimidine de farnésyl et/ou de géranylgéranyl pyrophosphate synthase
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
CN106727587A (zh) * 2016-11-28 2017-05-31 李娜 一种治疗心律失常的药物组合物
WO2018237084A1 (fr) 2017-06-21 2018-12-27 SHY Therapeutics LLC Composés interagissant avec la superfamille ras destinés à être utilisés dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH317906A (de) 1953-09-16 1956-12-15 Sandoz Ag Verfahren zur Herstellung von 1-Amino-4-oxyanthrachinonsulfonsäuren
AU521790B2 (en) 1977-05-23 1982-04-29 Ici Australia Limited Process for eradication of ticks
ZA782648B (en) 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
DD226893A1 (de) 1981-12-15 1985-09-04 Ralf Boehm Verfahren zur herstellung von arylaminosubstituierten thieno 2,3-d pyrimidinen
IL112568A0 (en) 1994-02-10 1995-05-26 Wyeth John & Brother Ltd Substituted quinolines, their preparation and pharmaceutical compositions containing them
IL112569A (en) 1994-02-10 1999-12-22 Wyeth John & Brother Ltd Pharmaceutical compositions comprising cyclohexylamine derivatives certain such novel compounds and their preparation
IL112567A (en) 1994-02-10 2000-02-29 Wyeth John & Brother Ltd Substituted quinolines their preparation and pharmaceutical compositions containing them
IL112566A (en) 1994-02-10 2000-10-31 Wyeth John & Brother Ltd Substituted quinolinones and pharmaceutical compositions containing them
EP0846119B1 (fr) 1995-08-17 2002-11-13 Takeda Chemical Industries, Ltd. Derives de thienopyrimidine, leur fabrication et leurs applications comme antagonistes de l'endotheline
US6083986A (en) 1996-07-26 2000-07-04 Icagen, Inc. Potassium channel inhibitors
EP0934296B1 (fr) 1996-07-26 2003-06-04 Nissan Chemical Industries, Limited Derives de chromane
US5935945A (en) 1996-10-31 1999-08-10 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
US5969017A (en) 1996-10-31 1999-10-19 Merck & Co., Inc. Methods of treating or preventing cardiac arrhythmia
RU2116309C1 (ru) 1997-02-13 1998-07-27 Институт медицинской паразитологии и тропической медицины им.Е.И.Марциновского 4-[(бензо-2,1,3-тиадиазолил-4)амино]-5,6,7,8-тетрагидробензотиено [2,3-d]пиримидин, обладающий противогельминтной активностью при ларвальном альвеолярном эхинококкозе
US6333337B1 (en) 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
EP1082315A1 (fr) 1998-06-05 2001-03-14 Icagen, Inc. Inhibiteurs des canaux de potassium
AU5444499A (en) 1998-09-01 2000-03-21 Nissan Chemical Industries Ltd. Benzoxazine derivatives
US6194458B1 (en) 1998-10-30 2001-02-27 Merck & Co., Inc. Benzamide potassium channel inhibitors
DE19929076A1 (de) 1999-06-25 2000-12-28 Aventis Pharma Gmbh Indanylsubstituierte Benzolcarbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
EP1212314B1 (fr) 1999-09-17 2005-11-30 Nissan Chemical Industries, Ltd. Derives de benzopyranne
US6555574B1 (en) 1999-09-24 2003-04-29 Nissan Chemical Industries, Ltd. 4-oxybenzopyran derivative
US6531495B1 (en) 1999-10-02 2003-03-11 Aventis Pharma Deutschland Gmbh 2′-Substituted 1,1′-biphenyl-2-carboxamides, processes for their preparation, their use as medicaments, and pharmaceutical preparations comprising them
DE19947457A1 (de) 1999-10-02 2001-04-05 Aventis Pharma Gmbh 2'-Substituierte 1,1'-Biphenyl-2-carbonamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie enthaltende pharmazeutische Zubereitungen
EP1218367A1 (fr) 1999-10-05 2002-07-03 Nissan Chemical Industries, Ltd. Derive de 4-oxybenzopyranne
US6887870B1 (en) 1999-10-12 2005-05-03 Bristol-Myers Squibb Company Heterocyclic sodium/proton exchange inhibitors and method
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2393756A1 (fr) 1999-12-21 2001-06-28 Aimee D. Reed Inhibiteurs des canaux potassiques
CA2421819C (fr) 2000-09-20 2010-03-09 Merck & Co., Inc. Isoquinolinone en tant qu'inhibiteurs du canal potassique
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10059418A1 (de) 2000-11-30 2002-06-20 Aventis Pharma Gmbh Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10060807A1 (de) 2000-12-07 2002-06-20 Aventis Pharma Gmbh Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10061876A1 (de) 2000-12-12 2002-06-20 Aventis Pharma Gmbh Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10104802A1 (de) 2001-02-02 2002-08-08 Merck Patent Gmbh Pharmazeutische Formulierungen enthaltend Thienopirimidine und Endothelin-Rezeptor-Antagonisten (1)
BR0206853A (pt) 2001-02-02 2004-01-13 Merck Patent Ges Mit Beschroen Formulação farmacêutica compreendendo pirazolo[4,3-d]pirimidinas e antagonistas de receptor de endotelina ou tienopirimidinas e antagonistas de receptor de endotelina
TW589305B (en) 2001-02-14 2004-06-01 Nissan Chemical Ind Ltd 4-aminobenzopyran derivatives
DE10121002A1 (de) 2001-04-28 2002-11-14 Aventis Pharma Gmbh Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen
DE10121003A1 (de) 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
DE10128331A1 (de) 2001-06-12 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide mit Heteroarylsulfonyl-Seitenkette, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
DE60206505T2 (de) 2001-06-25 2006-07-06 Nissan Chemical Industries, Ltd. Substituierte benzopyranderivate gegen arrhytmie
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
EP1641803B3 (fr) * 2003-06-11 2010-12-08 Xention Limited Utilisation de derives de la thienopyrimidine comme inhibiteurs des canaux potassiques
GB0315950D0 (en) 2003-06-11 2003-08-13 Xention Discovery Ltd Compounds
ZA200600197B (en) * 2003-07-02 2007-06-27 Vertex Pharma Pyrimidines useful as modulators of voltage-gated ion channels
WO2005066182A1 (fr) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Derives de thienopyrimidine et de thienopyridine substitues par un groupe amino cyclique
AU2005260077A1 (en) 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
US7576212B2 (en) 2004-12-09 2009-08-18 Xention Limited Thieno[2,3-B] pyridines as potassium channel inhibitors
JP5173429B2 (ja) 2004-12-09 2013-04-03 ゼンション・リミテッド 化合物
US20080108611A1 (en) 2006-01-19 2008-05-08 Battista Kathleen A Substituted thienopyrimidine kinase inhibitors
EP2043654A2 (fr) 2006-06-12 2009-04-08 Vertex Pharmaceuticals, Inc. Thiénopyrimidines utiles en tant que modulateurs de canaux ioniques
DE102009039893B4 (de) 2009-09-03 2012-03-29 Bundesanstalt für Materialforschung und -Prüfung (BAM) Verwendung eines Brennstoffs in einem selbstunterhaltenden pulsierenden Sauerstoff-Brennstoff-Verbrennungsprozess

Also Published As

Publication number Publication date
MX335937B (es) 2016-01-04
NI201300100A (es) 2014-01-07
GT201300225A (es) 2014-12-30
EP2694518B1 (fr) 2015-10-07
UA110131C2 (ru) 2015-11-25
US20140206703A1 (en) 2014-07-24
CN103492392A (zh) 2014-01-01
CY1117025T1 (el) 2017-04-05
SG193578A1 (en) 2013-10-30
ECSP13012988A (es) 2013-12-31
PE20141021A1 (es) 2014-08-30
RS54458B1 (en) 2016-06-30
BR112013025236A2 (pt) 2019-09-24
GB201105659D0 (en) 2011-05-18
CO6801756A2 (es) 2013-11-29
IL228555A0 (en) 2013-12-31
PT2694518E (pt) 2016-02-05
ME02314B (me) 2016-06-20
PL2694518T3 (pl) 2016-03-31
SI2694518T1 (sl) 2016-02-29
RU2013148627A (ru) 2015-05-10
TN2013000377A1 (en) 2015-01-20
HK1193806A1 (zh) 2014-10-03
CA2831493A1 (fr) 2012-10-04
JP5826374B2 (ja) 2015-12-02
KR20140023332A (ko) 2014-02-26
HRP20151340T1 (hr) 2016-02-26
CU24173B1 (es) 2016-04-25
TW201244720A (en) 2012-11-16
ZA201307085B (en) 2015-04-29
CN103492392B (zh) 2015-11-25
NZ615621A (en) 2015-01-30
HUE028438T2 (en) 2017-02-28
CL2013002789A1 (es) 2014-07-18
WO2012131379A1 (fr) 2012-10-04
US9249155B2 (en) 2016-02-02
SMT201500322B (it) 2016-02-25
DK2694518T3 (en) 2015-11-09
TWI516265B (zh) 2016-01-11
EA201301111A1 (ru) 2014-02-28
HK1193096A1 (zh) 2014-09-12
EP2694518A1 (fr) 2014-02-12
MX2013011301A (es) 2014-04-16
ES2558563T3 (es) 2016-02-05
AR088735A1 (es) 2014-07-02
AU2012235882A1 (en) 2013-05-02
JP2014509637A (ja) 2014-04-21
CR20130488A (es) 2013-12-06
AP2013007198A0 (en) 2013-10-31
CU20130124A7 (es) 2014-01-29
AU2012235882B2 (en) 2015-08-06

Similar Documents

Publication Publication Date Title
MA39092B1 (fr) Pyrrolo[2,3-d]pyrimidinyle, pyrrolo[2,3-b]pyrazinyle et pyrollo[2,3-d]pyridinyle acrylamides
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
EA201492216A1 (ru) Ингибиторы бромодомена и их применение
TN2012000146A1 (fr) Derives de pyrrolo[2,3-d]pyrimidine
EA200901157A1 (ru) Конденсированные кольцевые гетероциклические модуляторы киназы
EA202090662A2 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EA201291098A1 (ru) Новые соединения 3,5-дизамещенного-3h-имидазо[4,5-b]пиридина и 3,5-дизамещенного -3h-[1,2,3]триазоло[4,5-b]пиридина как модуляторы протеинкиназ
EA201400161A1 (ru) Замещенные гетероароматические пиразолсодержащие карбоксамидные и мочевинные производные в качестве лигандов ваниллоидных рецепторов
EA201170531A1 (ru) Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
MA35816B1 (fr) Dérivés d'aniline, leur préparation et leur application thérapeutique
UA114001C2 (xx) Оксазолідин-2-он-піримідинові похідні
MX342119B (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
MA35064B1 (fr) Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie
MA38678A1 (fr) Dérivés nucléosidiques 4'-azido, 3'désoxy-3'-fluoro substitués
UA111520C2 (uk) [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
MX2013002295A (es) 1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
GEP201706657B (en) Quinoline derivatives as pde10a enzyme inhibitors
EA201401142A1 (ru) Замещенные 6-аминоникотинамиды, несущие он-содержащую группу, в качестве модуляторов kcnq2/3